Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sotorasib in Stage III Unresectable NSCLC KRAS p.G12C Patients
NCT05398094Phase 2Recruiting
- Sponsor
- Fundación GECP
- Start
- Mar 2022
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sotorasib in non-small cell lung cancer (NSCLC), sponsored by Fundación GECP. Primary endpoint: Progression Free Survival at 12 months. Started Mar 2022; status: recruiting.
02
Drugs
sotorasib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05398094.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05398094.